Clinical Trials Browser

Ovarian Neoplasms

NCT07213804 2026-04-17

FRAmework-01

Phase 3 Recruiting

1,080 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

Phase 3 Recruiting

466 enrolled

Gynecologic

Ovarian Neoplasms

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

450 enrolled

Gynecologic

Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06619236 2026-03-03

RAINFOL-02

Phase 3 Active not recruiting

530 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

417 enrolled

Gynecologic

Ovarian Neoplasms

NCT00657878 2023-11-13

MITO-8

Phase 3 Unknown

215 enrolled

Gynecologic

Ovarian Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01802749 2023-03-24

MITO16MANGO2b

Phase 3 Unknown

406 enrolled

Gynecologic

Ovarian Neoplasms

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase 3 Terminated

9 enrolled

Gynecologic

Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

427 enrolled

Gynecologic

Ovarian Neoplasms

NCT02903004 2021-08-25

MITO23

Phase 3 Completed

242 enrolled

Gynecologic

Ovarian Neoplasms

NCT00011986 2019-04-16

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 3 Completed

4,312 enrolled 14 charts

Gynecologic

Ovarian Neoplasms

NCT00434642 2017-08-09

OCEANS

Phase 3 Completed

484 enrolled 12 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01684878 2017-05-23

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Phase 3 Completed

208 enrolled 19 charts

Gynecologic

Ovarian Neoplasms

NCT00006453 2015-12-23

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

Phase 3 Completed

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00191646 2011-03-04

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Phase 3 Completed

919 enrolled 18 charts

Gynecologic

Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms

NCT00191607 2007-01-26

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Phase 3 Completed

162 enrolled

Gynecologic

Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms

NCT00102414 2006-11-14

Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Phase 3 Completed

356 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence, Disease Progression

NCT00312988 2006-04-11

Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy

Phase 3 Completed

450 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

A Study of SHR-A1811 in Subjects With Ovarian Cancer

FRAmework-01

MAESTRA 2

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

RAINFOL-02

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

ARTISTRY-7

ANITA

MITO-8

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

MITO16MANGO2b

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

NItCHE-MITO33

MITO23

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

OCEANS

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy